Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Antibody Persistence of Bexsero at 18 Months
NCT01148524Phase 3Completed
- Sponsor
- Novartis
- Start
- Aug 2010
- Primary completion
- Jan 2012
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, open-label trial of recombinant neisseria meningitidis group B nhba fusion protein in meningococcal disease (9 arms), sponsored by Novartis. Primary endpoints: Percentage of Subjects With hSBA Titers >= 1:4 Against Meningococcal Strains, Geometric Mean hSBA Titers Directed Against Meningococcal Strains and 2 more. Started Aug 2010; status: completed.
02
Drugs
recombinant neisseria meningitidis group B nhba fusion protein
03
Conditions
meningococcal disease
Beyond the preview
Go deeper on NCT01148524.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01148524.